Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ah, FDA approved RSBQ-AUC for primary endpoint, how wonderful!
New article TODAY
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
To be fair he said, FUDsters, which would only apply to YOU, if the shoe fits.
It's comments like this that reveal the real FUDspects...
Yup a shorts dream is for us long investors to sell our shares to them.
I have something to say about that:
PAY UP!!!
I haven’t denied that. So that’s another False comment on your part. So you are spreading more FUD!!!
Agreed. You have to wonder why, if there is truly so much corruption in the stock market and specifically a global cabal attacking a tiny biotech company, that these people don’t sell their stock and invest elsewhere. There are plenty of good investment opportunities, such as municipal bonds, which are very attractive right now, or large-cap stocks that pay good dividends.
You can buy these and sleep well at night without having to worry about a cabal.
that was my point in response..
It was rhetorical..
This is the reality and the reason why I think management has failed this drug. There is clear effect that can't be denied.
The titration issue was a death nell for the company...they should have had that cleared up or at least done interim analysis like sava to reduce the titration to save the study.
it is just one misstep after another...and all missling cares about is presenting at conferences.
I found it... no problem. Excellent article!
Actually when you click on the link this full article comes up
See the title below,
Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function
Author links open overlay panelAlba Vera-Zambrano a b c, Maria Baena-Nuevo b, Susanne Rinné d, Marta Villegas-Esguevillas c e f, Bianca Barreira c e f, Gokcen Telli g, Angela de Benito-Bueno b, José Antonio Blázquez h, Belén Climent i, Francisco Pérez-Vizcaino c e f, Carmen Valenzuela b j, Niels Decher d, Teresa Gonzalez a b i, Angel Cogolludo c e f
a
Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
b
Instituto de Investigaciones Biomédicas “Alberto Sols” CSIC-UAM, Madrid, Spain
c
Department of Pharmacology and Toxicology, School of Medicine, University Complutense of Madrid, Madrid, Spain
d
Institute of Physiology and Pathophysiology, Vegetative Physiology, University of Marburg, 35043 Marburg, Germany
e
Ciber Enfermedades Respiratorias (CIBERES), Spain
f
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
g
Hacettepe University, Department of Pharmacology, Faculty of Pharmacy, Ankara, Turkey
h
Departamento de Cirugía Cardiaca, Hospital Universitario La Paz, Madrid, Spain
i
Department of Physiology, Faculty of Pharmacy, University Complutense of Madrid, Madrid, Spain
j
Spanish Network for Biomedical Research in Cardiovascular Research (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
Received 29 November 2022, Revised 23 January 2023, Accepted 1 February 2023, Available online 3 February 2023, Version of Record 6 February 2023.
https://www.sciencedirect.com/science/article/pii/S1043661823000403?via%3Dihub
b]GOD bless,
I clicked on your article, ctrl+f Anavex and there were zero results. Seems desperate man...
Do the math... Either the interest isn't there or they're getting lowball offers.
Not all, but many... I'm sure you're well aware that the organized cabal target many small-cap companies, though some HFs specialize in the price manipulation of biotechs (easy prey).
You know, the seven HFs/MMs that have been sued for illegal trading practices using spoofing and naked shorting.
Data will be released in plenty of time to see approvals this year in AU & EU... The compromised FDA may come around a bit later.
Every group of investors on the internet is convinced there is a massive global campaign solely focused on their snowflake investment. Truly a fascinating phenomenon...
I wouldn't. You need data released first. The FDA isn't going to approve just because some dudes typed in all caps on message boards
Sorry georgejjl
You are the red herring...time to place you on ignore.
Just a total bunch of effing AHs on this board!
Fully agree. If Rett gets approved, that funding can take it to market at much higher levels.
"Anavex's blarcamesine and/or Anavex 3-71 can be used to treat and/or prevent cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF). "
Please stop with this nonsense. Let's get current trials moving forward. This other nonsense is decades away. Besides, we will ALL be dead by the time we see any trial results.
...and notice that it's $150M (not shares). If they wait until after approval, then the number of shares needed to exercise are much less, perhaps as little as 1/10th.
Not with the XBI up 1%.
The key point is that Missling is a liar stating bi further dilution after diluting on the spike to 30+ with 4+ years in the bank. I guess he now sees that there won't be an approval or revenue within at least the next 3 to 4 years.
Not sure why you're thinking expiration date (7/5) is a critical date, when he can simply choose to exercise and hold the shares for as long as he'd like. The strike-price cost is the same.
The key point is that AVXL is in full control of any selling... if/when they decide it's needed.
Yes, this is a great point.
I would hope they are in negotiation and this is reinforcement for position.
https://www.mdbneuro.com/hubfs/Inflammatory%20Biomarker%20whitepaper_Feb_2023-MDBneuro.pdf
FYI - No paywall but you need to register.
Although it's a price cut, if you factor in the $150m new shares that can be coming it is almost the exact same adjusted. Maybe they just anticipate full saturation of those shares.
The only "red flags" here are non-stop FUDspects.
So why would
A company that has such great data and p3 data not just partner w the plethora of pharma interested in our stock on favorable non dilutive terms?
They already said they would partner for AD
Where is your data showing 50% plus (your word = "most") companies at this stage are diluting 10% per year?
Anavex will provide whatever measurement the FDA has requested... period!
With the larger trial, the CGI-anchored RSBQ may be all that the FDA wants to see. If they require, RSBQ-AUC, then that will be provided. It's all up to what the FDA and the other agencies want to see. You're making way too much of this, but we get it.
Yes Steady_T, it will certainly be interesting to see how FitzyP33 makes out with his AVXL short position, won't it? Too bad for him that he didn't initiate his position yesterday morning...he would already be up nearly 8%!
I meant a meaningful difference. Okay, so the LPC agreement has a partial upfront payment instead of spreading out the payment. The timing of that immaterial fee implies the “disaster” that the fudsters claim this deal indicates?
That’s the problem with FUD. It doesn’t hold up against scrutiny.
This dilution narrative is wrong. Total shares are up less than 3% from a year ago and most companies at this stage are diluting 10%+ per year. AVXL is doing a terrific job managing funding and dilution.
Yea no coincidence following a short attack, on a RISK-OFF day, for price cuts to be announced.
It is how the game is played, the sucker game at least.
Missing the trees for the forest is the goal, $28 seems to be a pretty good gain from today.
However the NARRATIVE IS: price is CUT!
The only reason why you want a Goldman Sachs or a J.P. Morgan to get the deal is for the guidance that comes with it. Wouldn’t it be great to have a strong buy recommendation from a big name institution?? This where Missling is short sighted? He doesn’t care about the stock price today. He knows where it will be on approval or some other big milestone. Since retail is the majority of holders, he just doesn’t care. He would rather have us slowly turn our shares over to the tutes. And the tutes are happy because they are getting cheap shares.
Btig cuts price target today for Anavex from $35 to $28--perhaps if TGD met his predicted timelines...PDDOLE--FragileX--undisclosed rare disease -complete AD trial readout--come'on Dr.----lots to report on----many people waiting !!
Thank you Doc, your knowledge of this things never stops to amaze me.
In my opinion you sound like you are hedge fund Doctor of sort.
Maybe they are teaching these things in medical school now days.
GL with your "very small AVXL position".
Looks like an ATM to me, but how would you name this potential capital raise?
Can't wait to see that gap close inthe low 9's...I accidentally said 8's yesterday but meant 9's.
LOL...is HC Wainwright going to reiterate rating every day the share price drops...talk about pumping...
"Yesterday was an opportunity, RISK OFF DAY, for shorts to cover a few shares.
Did they take advantage, or did they add?
We should find out today, no?"
You do realize that the short interest report that comes out later today is two weeks old, don't you?
I agree with your view, however ATM financing is normally considered by most as a "bad thing" associated with a company in trouble so your reference to bad news pending such as a failure of some sort (Alzheimer Data?) might be a reason for the short sellers to step on the neck of Anavex Life Sciences Corp
...but I do believe that Chris Missling has a reason to protect the outlook for the share price..........
Why?,,,,,,,,,he has 500,000 low strike options @$1.67 which must be exercised in the near future (July 5th).....this might be a good time to "do a deal" before releasing some good news albeit he would have absolutely NO problem with the SEC if he exercised and became a shareholder (like us) at any time! He is allowed to exercise those even before or on the day of 8K information of a material event...that is a FACT
The Cantor arrangement is a straightforward ATM with a 3% commission at each trade. AVXL used 42M of the 50M max and then renewed a new 50M allowance. The LPC price is not ATM.
I mean does a bear shit in the woods?
You are presenting your short thesis as if the board didnt already know you were already short LOL.
It would be nice if others would join you in stating the obvious and stopped pretending to be "long share holders".
Oh wait.....
The "cabal" you hate is the real world, with obstacles and all, that of which ALL companies have to overcome.
Sounds like you are taking this AVXL "investment" personal.
Maybe you should read this book to manage your expectations, since apparently your experience has not taught you as much as you think.
From Breakthrough to Blockbuster: The Business of Biotechnology
by Donald L. Drakeman (Author), Lisa N. Drakeman (Author), Nektarios Oraiopoulos (Author)
Yesterday was an opportunity, RISK OFF DAY, for shorts to cover a few shares.
Did they take advantage, or did they add?
We should find out today, no?
Higher lows, and higher borrow rates, makes a bear wonder WTF is going on, why aren't these losers selling to us at lower prices??
Followers
|
1075
|
Posters
|
|
Posts (Today)
|
105
|
Posts (Total)
|
463338
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |